Association Review
In brief The association between MYC (MYC Proto-Oncogene, BHLH Transcription Factor) and Prostate Cancer is reported, with clinical genetic testing available, supported by 2 contributing sources.
Sources
2
Clinical variants
0
Symptoms
5
Compounds
0
Trials
0
Publications
50
Contents
01
At a glance
Association overview A cited synthesis of the gene–disorder association, with a clinical-actionability summary where the evidence supports one.
Request access 02
Provenance
Evidence and sources 2 sources
Every contributing database and publication behind this association, with evidence type, strength, accessions and deep links.
Request access 1 source summary
A gene summary alongside the source descriptions it was distilled from.
Request access 04
Prostate Cancer
The disorder 20 database identifiers
The disorder’s summary, prevalence, aliases and cross-reference identifiers (OMIM, Orphanet, MONDO, ICD-10, MedGen).
Request access 05
Phenotype
Clinical features 1 clinical feature
The disorder’s clinical features (HPO) grouped by body system, each with observed frequency and penetrance.
Request access 06
Population genetics
GWAS signals 3 GWAS phenotypes
Gene-associated GWAS phenotypes matching the disorder, with best SNP, score, risk-allele frequency and effect size.
Request access 07
Genomic context
Regulatory context 11 regulatory elements
GeneHancer regulatory elements for the pair, with coordinates, score, element type and supporting literature.
Request access 08
Mechanism overlap
Shared mechanisms 2 shared pathways
Biological pathways and phenotype concepts shared by the gene and the disorder, with supporting publications.
Request access 50 publications
Publications linking the gene and the disorder, with title, authors, journal, year and citation metrics.
Request access 10
Provenance
References & sources 23 references
Every source and publication cited across this dossier, as one numbered reference list.
Request access 
